Document Detail


Adverse reactions to thrombolytic agents. Implications for coronary reperfusion following myocardial infarction.
MedLine Citation:
PMID:  3306267     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The use of thrombolytic agents to dissolve coronary artery thrombi causing acute transmural myocardial infarctions has been shown to decrease short term mortality, and improve left ventricular function, in patients with acute transmural myocardial infarction. Several thrombolytic agents are currently available which differ mainly in cost, antigenicity, and mechanism of action. Current investigations are being directed at finding safer, more effective thrombolytic agents and at developing optimal therapy following thrombolysis. The complications of thrombolytic therapy are for the most part minor and reversible. Immediate and delayed hypersensitivity to streptokinase is rare. Hypotension and arrhythmias commonly accompany myocardial reperfusion and are usually benign and self-limited. Haemorrhagic complications are the most frequent and serious problems following the use of thrombolytic agents. They can be lessened by the proper selection of patients to avoid those at high risk of bleeding. The avoidance of unnecessary arterial and venous punctures will decrease the incidence of minor but annoying local bleeding. Those agents which are activated at the site of thrombi will hopefully cause fewer bleeding episodes, but early experience with these agents has not been able to demonstrate a lower rate. With careful attention to patient selection and follow-up, thrombolytic agents can be safely and effectively used in the management of patients with acute myocardial infarction.
Authors:
J Nazari; R Davison; K Kaplan; D Fintel
Related Documents :
7560617 - Cost-effectiveness of captopril therapy after myocardial infarction.
11005467 - The current role of thrombolytic therapy for pulmonary embolism.
9034237 - Antiinflammatory activity of tissue plasminogen activator in the carrageenan rat footpa...
3154687 - What is established in thrombolytic therapy of acute myocardial infarction? pharmacolog...
8126027 - Physicochemical properties of calcific deposits isolated from porcine bioprosthetic hea...
8166057 - Acute angiographic and clinical results of long balloon percutaneous transluminal coron...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Medical toxicology and adverse drug experience     Volume:  2     ISSN:  0113-5244     ISO Abbreviation:  Med Toxicol Adverse Drug Exp     Publication Date:    1987 Jul-Aug
Date Detail:
Created Date:  1987-10-02     Completed Date:  1987-10-02     Revised Date:  2014-07-25    
Medline Journal Info:
Nlm Unique ID:  8709214     Medline TA:  Med Toxicol Adverse Drug Exp     Country:  NEW ZEALAND    
Other Details:
Languages:  eng     Pagination:  274-86     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Coronary Circulation
Coronary Disease / drug therapy*
Coronary Thrombosis / drug therapy*,  physiopathology
Fibrinolytic Agents / adverse effects*
Humans
Plasminogen Activators / adverse effects
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; EC 3.4.21.-/Plasminogen Activators

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical features and management of poisoning due to antimalarial drugs.
Next Document:  Systemic reactions to ophthalmic drug preparations.